UNDATED (WKRC) - Weight-loss medications may not be as effective in "real-world" settings as they are in clinical trials, ...

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

Despite an increase in the prevalence of prescribing, only 0.5% of U.S. adolescents with obesity were prescribed an obesity ...

Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months.

An investigational drug developed by Eolo Pharma is showing promise in animal experiments and an early human trial. It could eventually be an alternative or add-on to popular GLP-1 medications.

Former FDA chief Dr. David Kessler says the new weight-loss drugs are a powerful tool to fight obesity. But they come with ...

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the ...

Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.

A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...

Variants of obesity-related genes influence how much weight patients lose on specific weight loss drugs like liraglutide, two studies report.

A study from Mass General Brigham and Harvard Medical School raises questions about a new class of weight loss drugs — and ...

Since the FDA said shortages of Wegovy and Zepbound are over, compounding pharmacies are supposed to stop making copies of the drugs. But some of those business are trying to find ways to continue.